United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - midodrine hydrochloride (unii: 59jv96ytxv) (midodrine - unii:6ye7pbm15h) - midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (oh). because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure (bp > 200 mmhg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. the indication is based on midodrine hydrochloride tablets's effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. at present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to perform life activities, have not been established. further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets. after initiation of treatment, midodrine hydrochloride tablets should be continued only for patients who rep

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduces the blood ammonia level by 25 to 50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose solution therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals inc. - bethanechol chloride (unii: h4qbz2lo84) (bethanechol - unii:004f72p8f4) - bethanechol chloride 5 mg - bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. hypersensitivity to bethanechol chloride tablets, hyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or hypotension, vasomotor instability, coronary artery disease, epilepsy and parkinsonism. bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question, or in the presence of mechanical obstruction; when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful, as following recent urinary bladder surgery, gastrointestinal resection and anastomosis, or when there is possible gastrointestinal obstruction; in bladder neck obstruction, spastic gastrointestinal disturbances, acute inflammatory lesions of the gastrointestinal tract, or peritonitis; or in marked vagotonia.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate 300 mg - lithium carbonate extended-release tablet is indicated in the treatment of manic episodes of bipolar disorder. bipolar disorder, manic (dsm-iv) is equivalent to manic depressive illness, manic, in the older dsm-ii terminology. lithium carbonate extended-release tablet is also indicated as a maintenance treatment for individuals with a diagnosis of bipolar disorder. maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. when given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide topical oil, 0.01% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section). pediatric use: fluocinolone acetonide topical oil, 0.01% may be used twice daily for up to 4 weeks in pediatric patients 2 years and older with moderate to severe atopic dermatitis.  fluocinolone acetonide topical oil, 0.01% should not be applied to the diaper area. application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. the smallest amount of drug needed to cover the affected areas should be applied. long term safety in the pediatric population has not been established. fluocinolone acetonide topical oil, 0.01% is not recommended for use on the face (see adverse reactions section). because of a higher ratio of skin surface area to body mass, children are at

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate extended-release tablets is indicated in the treatment of manic episodes of manic-depressive illness. maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania.  typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. when given to a patient experiencing a manic episode, lithium carbonate extended-release tablets may produce a normalization of symptomatology within 1 to 3 weeks.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recomme

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets, usp reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology, pharmacodynamics and clinical effects). losartan potassium is contraindicated in patients who are hypersensitive to any component of this product. do not co-administer aliskiren with losartan potassium in patients with diabetes. read the patient information that comes with losartan potassium tablets before you start taking it and each ti

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc - amiloride hydrochloride anhydrous (unii: 7m458q65s3) (amiloride - unii:7dzo8eb0z3) - amiloride hydrochloride 5 mg - amiloride hcl tablets are indicated as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension to:                a. help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic                b. prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. amiloride hcl tablets have little additive diuretic or antihypertensive effect when added to a thiazide diuretic. amiloride hcl tablets should rarely be used alone. it has weak (compared with thiazides) diuretic and antihypertensive effects. used as single agents, potassium sparing diuretics, including amiloride hcl tablets, result in an increas

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - probenecid 500 mg - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animal under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of child bearing potential requires that the anticipated benefit be weighed against the possible hazards.